Levothyroxine impurities can form during API synthesis and formulation due to degradation reactions, such as oxidation, hydrolysis, or halogenation, which occur under specific conditions like temperature, pH, or exposure to light. These impurities may arise from incomplete reactions or the interaction of the active ingredient with excipients during formulation.

Levothyroxine 3,5-Diiodo 4-Hydroxybenzoic Acid
CAS No: 618-76-8

Levothyroxine EP Impurity D
CAS No: 67-30-1

Levothyroxine EP Impurity H
CAS No: 2055-97-2

Levothyroxine Ethyl Ester
CAS No: 76353-71-4

Levothyroxine Hydroxyphenoxy Aldehyde Impurity
CAS No: 2828-49-1

Levothyroxine Impurity C
CAS No: 51-24-1

Levothyroxine Methoxyphenoxy Aldehyde Impurity
CAS No: 69240-57-9

Levothyroxine N-Acetyl Impurity
CAS No: 26041-51-0

Levothyroxine N-Formyl Impurity
CAS No: 671235-41-9

Levothyroxine N-Methylamide
CAS No: 2088032-52-2

Levothyroxine T4-Formic Acid-N-Methylamide
CAS No: 2088032-78-2